{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T12:43:49Z","timestamp":1705754629218},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Burn patients have numerous risk factors for multidrug-resistant organisms (MDROs) and altered pharmacokinetics, which both independently increase the risk of treatment failure. Data on appropriate antimicrobial dosing are limited in this population and therapeutic drug monitoring (TDM) for beta-lactams is impractical at most facilities. Technology is available that can detect genetic markers of resistance, but they are not all encompassing, and often require specialized facilities that can detect less common genetic markers. Newer antimicrobials can help combat MDROs, but additional resistance patterns may evolve during treatment. Considering drug shortages and antimicrobial formularies, clinicians must remain vigilant when treating infections. This case report describes the development of resistance to ceftazidime-avibactam in a burn patient. The patient was a 54-year-old burn victim with a 58% total body surface area (TBSA) thermal burn who underwent multiple courses of antibiotics for various Pseudomonal infections. The initial Pseudomonal wound infection was sensitive to cefepime, aminoglycosides, and meropenem. A subsequent resistant pseudomonal pneumonia was treated with ceftazidime-avibactam 2.5 g every 6 hours due to the elevated MIC to cefepime (16 mcg\/mL) and meropenem (&amp;gt;8 mcg\/mL). Although the patient improved over 7 days, the patient again spiked fevers and had increased white blood counts (WBC). Repeat blood cultures demonstrated a multidrug-resistant (MDR) Pseudomonas with a minimum inhibitory concentration (MIC) to ceftazidime-avibactam of 16 mcg\/mL, which is above the Clinical and Laboratory Standards Institute (CLSI) breakpoint of 8 mcg\/mL. At first, resistance was thought to have occurred due to inadequate dosing, but genetic work demonstrated multiple genes encoding beta-lactamases.<\/jats:p>","DOI":"10.1093\/jbcr\/irab160","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T15:23:26Z","timestamp":1629818606000},"page":"474-478","source":"Crossref","is-referenced-by-count":3,"title":["When More Is Still Not Enough: A Case of Ceftazidime-Avibactam Resistance in a Burn Patient"],"prefix":"10.1093","volume":"43","author":[{"given":"Shelbye R","family":"Herbin","sequence":"first","affiliation":[{"name":"Detroit Receiving Hospital, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie E","family":"Barber","sequence":"additional","affiliation":[{"name":"University of Mississippi School of Pharmacy, Jackson, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Michael and Marian Ilitch Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather S","family":"Dolman","sequence":"additional","affiliation":[{"name":"Michael and Marian Ilitch Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica D","family":"McGee","sequence":"additional","affiliation":[{"name":"Detroit Receiving Hospital, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Alfred E","family":"Baylor","sequence":"additional","affiliation":[{"name":"Michael and Marian Ilitch Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA"},{"name":"Hyperbaric and Wound Care Center, Wayne State University School of Medicine\/Detroit Receiving Hospital, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G","family":"Tyburski","sequence":"additional","affiliation":[{"name":"Michael and Marian Ilitch Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA"},{"name":"Detroit Receiving Hospital, Wayne State University School of Medicine, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T","family":"White","sequence":"additional","affiliation":[{"name":"Detroit Receiving Hospital, Michigan, USA"},{"name":"Michael and Marian Ilitch Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janie","family":"Faris","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"2022032516093864300_CIT0001","author":"Antibiotic\/Antimicrobial Resistance","year":"2020"},{"key":"2022032516093864300_CIT0002","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/CCM.0b013e318180fe62","article-title":"Antibiotic resistance-what\u2019s dosing got to do with it?","volume":"36","author":"Roberts","year":"2008","journal-title":"Crit Care Med"},{"key":"2022032516093864300_CIT0003","author":"The VERIGENE System"},{"key":"2022032516093864300_CIT0004","article-title":"BD.","author":"BD Pheonix Automated Identification and Susceptibility Testing System"},{"key":"2022032516093864300_CIT0005","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamics (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2022032516093864300_CIT0006","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.clinthera.2013.08.014","article-title":"Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice ia Monte Carlo simulations","volume":"35","author":"Conil","year":"2013","journal-title":"Clinical Therapeutics"},{"key":"2022032516093864300_CIT0007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/BCR.0000000000000147","article-title":"Pharmacokinetic and pharmacodynamics of antibacterial and antifungal agents in adult patients with thermal injury; a review of current literature","volume":"36","author":"Ortwine","year":"2015","journal-title":"J Burn Care Res"},{"key":"2022032516093864300_CIT0008","volume-title":"[package insert]. Madison (NJ):","author":"Avycaz","year":"2019."},{"key":"2022032516093864300_CIT0009","article-title":"Performance Standards for Antimicrobial Susceptibility Testing","volume-title":"CLSI guideline M100-2D:2020","author":"CLSI.","year":"2020","edition":"30"},{"key":"2022032516093864300_CIT0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2125.2003.01915.x","article-title":"Population pharmacokinetics of ceftazidime in burn patients","volume":"56","author":"Dailly","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"2022032516093864300_CIT0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2007.02857.x","article-title":"Assessment of renal function in clinical practice at the bedside of burn patients","volume":"64","author":"Conil","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"2022032516093864300_CIT0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"key":"2022032516093864300_CIT0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/jac\/dki482","article-title":"OXA- type carbapenemases","volume":"57","author":"Walther-Rasmussen","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2022032516093864300_CIT0014","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022032516093864300_CIT0015","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomized open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022032516093864300_CIT0016","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: a novelaminoglycoside for the treatment of resistant Gram-negative bacterial infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"key":"2022032516093864300_CIT0017","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-lactams strike back: ceftazidime-avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2022032516093864300_CIT0018","doi-asserted-by":"crossref","first-page":"e01379","DOI":"10.1128\/AAC.01379-18","article-title":"Mutation-driven evolution of Pseudomonas aeruginosa in the presence of either ceftazidime or ceftazidime- avibactam","volume":"62","author":"Sanz-Garcia","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irab160\/40312297\/irab160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/43\/2\/474\/42981415\/irab160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/43\/2\/474\/42981415\/irab160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T20:32:55Z","timestamp":1648240375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/43\/2\/474\/6357068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,24]]},"published-print":{"date-parts":[[2022,3,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/irab160","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,8,24]]}}}